Get the Stockscreener App
1.67
5.65%
-0.10
After Hours:
1.70
0.03
+1.80%
Gri Bio Inc stock is traded at $1.67, with a volume of 104.98K.
It is down -5.65% in the last 24 hours and up +6.37% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$1.77
Open:
$1.82
24h Volume:
104.98K
Relative Volume:
0.62
Market Cap:
$2.96M
Revenue:
-
Net Income/Loss:
$-10.91M
P/E Ratio:
-0.021
EPS:
-79.5513
Net Cash Flow:
$-12.14M
1W Performance:
+13.61%
1M Performance:
+6.37%
6M Performance:
-27.71%
1Y Performance:
-95.86%
1-Day Range:
$1.66
$1.82
1-Week Range:
$1.50
$2.55
52-Week Range:
$1.36
$80.36
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.67 | 3.45M | 0 | -10.91M | -12.14M | -79.55 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GRI Bio, Inc. 2Q 2026: Net income $(1.64)M, EPS $(0.91) — 10-Q Summary - TradingView
Form 10-Q GRI Bio, Inc. For: Jun 30 - streetinsider.com
GRI Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
GRI Bio (GRI) investors disclose 4.99% stake capped by warrant blockers - Stock Titan
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Q2'26 Earnings: revenue estimate is 0 USD - TradingView
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GRI Bio Inc expected to post a loss of $1.19 a shareEarnings Preview - TradingView
GRI Bio Inc. (NASDAQ: GRI) Share Price, GRI Stock News, GRI Share Price & Updates - kalkine.com.au
GRI Bio Inc (GRI) Cash Flow - TradingKey
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GRI|GRI Bio Inc|Price:1.420|Chg%:-0.030 - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
GRI Bio Inc (GRI) Income Statement - TradingKey
Gri Bio, Inc. (GRI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio, Inc. Revenue Breakdown – NASDAQ:GRI - TradingView
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GRI Bio Inc. (GRI) Retreats 3.23% as Shares Test Support Near $1.42Price Surge Stocks - dars.gov.et
GRI Q1 2026 Earnings: Wider-than-Expected Loss on No RevenueWeak Earnings Momentum - dars.gov.et
GRI Bio Inc. (GRI) Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue StageConsensus Miss Rate - dars.gov.et
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by 76%, Stock Rises 2.6% Amid Strategic Progress - Bölüm Sonu Canavarı
GRI Bio Inc. (GRI) Q1 2026 Earnings: Wider-than-Expected Loss Exceeds Estimates on Pre-Revenue StatusTech Earnings Analysis - dars.gov.et
Price to earnings forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue AbsentSubscription Growth Report - dars.gov.et
GRI Bio Inc. (GRI) Declines Over 8%, Approaching Critical Support at $1.73Liquidity Order Flow - dars.gov.et
GRI Q1 2026 Earnings: EPS Misses Estimates by 76%, Shares Slide 8%Mid-Term Outlook - dars.gov.et
Price to sales forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to revenue forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by over 76% as Pre-Revenue Biotech Continues DevelopmentInterim Report - dars.gov.et
Enterprise value to EBIT forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Price to earnings forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBIT forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBITDA forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Q1 2026 Earnings: EPS Miss Widens Losses as Pre-Revenue Biotech Stock RalliesProfit Margin Analysis - DonanımHaber
ADTX Stock Price and Chart — OTC:ADTX - TradingView
GRI Bio, Inc. Actuals & Estimates (NASDAQ:GRI) - TradingView
GRI Forecast — Price Target — Prediction for 2027 - TradingView
GRI Bio Inc. (GRI) Rallies 3.8% as Momentum Builds Above Key SupportBollinger Expansion - dars.gov.et
GRI Bio Inc (GRI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GRI Bio Inc. (GRI) Edges Lower Near Support Amid Biotech Sector VolatilityFibonacci Arc - dars.gov.et
GRI Bio Inc. (GRI) Faces Steep Decline as Shares Test Key Support LevelsEarly Entry Signals - dars.gov.et
GRI Bio Secures FDA Orphan Drug Status for IPF - TipRanks
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):